5439-08-7Relevant academic research and scientific papers
Preparation method of vadadustat
-
Paragraph 0047-0053, (2020/04/02)
The invention provides a preparation method of vadadustat, and belongs to the field of pharmaceutical chemical industry. The method comprises the following steps: mixing 3,5-dichloro-2-picolinic acid,methanol and sulfuric acid at a certain temperature, and carrying out a reaction to obtain 3,5-dichloro-2-picolinic acid methyl ester; adding 3-chlorophenylboronic acid, and carrying out a catalyticreaction to obtain 5-(3-chlorphenyl)-3-chloropyridine-methyl formate; and adding glycine into the 5-(3-chlorphenyl)-3-chloropyridine-methyl formate, and carrying out a reaction to obtain the 5-(3-chlorphenyl)-3-chloropyridine-methyl formate. The method has the characteristics of high product purity, high yield, low cost, simple operation and stable process.
TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
-
Paragraph 00204; 00205, (2017/07/06)
The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
FAAH INHIBITORS
-
Page/Page column 153-154, (2012/07/13)
The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the com
NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES
-
Page/Page column 24, (2009/12/28)
The invention is concerned with novel heteroaryl carboxamide derivatives of formula (I), wherein m, X, Y, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically accepta
